Gregory T. DiNoia
Net Worth
Last updated:
What is Gregory T. DiNoia net worth?
The estimated net worth of Mr. Gregory T. DiNoia is at least $3,027,240 as of 21 Jun 2022. He owns shares worth $255,143 as insider, has earned $605,257 from insider trading and has received compensation worth at least $2,166,840 in Mesa Laboratories, Inc..
What is the salary of Gregory T. DiNoia?
Mr. Gregory T. DiNoia salary is $361,140 per year as Senior Vice President of Commercial Operations in Mesa Laboratories, Inc..
How old is Gregory T. DiNoia?
Mr. Gregory T. DiNoia is 60 years old, born in 1965.
What stocks does Gregory T. DiNoia currently own?
As insider, Mr. Gregory T. DiNoia owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Mesa Laboratories, Inc. (MLAB) | Senior Vice President of Commercial Operations | 3,634 | $70.21 | $255,143 |
What does Mesa Laboratories, Inc. do?
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Gregory T. DiNoia insider trading
Mesa Laboratories, Inc.
Mr. Gregory T. DiNoia has made 9 insider trades between 2019-2022, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 1,211 units of MLAB stock on 16 Jun 2021. As of 21 Jun 2022 he still owns at least 3,634 units of MLAB stock.
Mesa Laboratories key executives
Mesa Laboratories, Inc. executives and other stock owners filed with the SEC:
- Mr. Brian David Archbold (50) Senior Vice President of Continuous Improvement & Operations
- Mr. Gary M. Owens (57) Chief Executive Officer, Pres & Director
- Mr. Gregory T. DiNoia (60) Senior Vice President of Commercial Operations
- Mr. John V. Sakys (56) Chief Financial Officer & Chief Accounting Officer